Skip to content
value.today

iSpecimen Inc.

ISPC
$5 Mmarket cap on Oct 30, 2026-8.6% since Jan 2024
Compare
World rank
#27,026
Revenue
—
For year ending December-2025
Net income
$-10 M
SEC filing
Employees
—

iSpecimen Inc. in brief

iSpecimen Inc. is a listed company in the Diagnostics and Research industry, based in Woburn, Massachusetts, USA. Its market value was $5 M on 30 October 2026, which makes it the 27,026th largest listed company in the world and the 4,420th largest in the USA on this site. Its largest product and service lines by sales in 2025 were Shipping and other (10%). Its shares trade under the symbol ISPC (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About iSpecimen Inc.

iSpecimen’s mission is to accelerate life science research, discovery and development with a global marketplace platform that connects researchers to subjects, specimens, and associated data. Our vision is to create an “Amazon-like” global Marketplace of patients, biospecimens, and data for research to improve the quality of human life. We implement employee programs that foster a company culture predicated on the core values of corporate and individual growth, results and accountability, team before self; a can-do positive attitude, and the perseverance to succeed.

iSpecimen is technology-driven company founded to address a critical challenge: how to connect life science researchers who need human biofluids, tissues, and living cells for their research, with the billions of biospecimens available (but not easily accessible) in healthcare provider organizations worldwide. Our ground-breaking iSpecimen Marketplace platform was designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery.

From the company's annual report filed with the US SEC: read the report

iSpecimen Inc. timeline

3 events, 2012–2021
  1. 2012
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 💰
    Record revenue of $11 million
    FY2021, the highest of the 5 years on record.
  5. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 21 June 2021; shares registered for exchange trading on 14 June 2021.

Events of iSpecimen Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$16 M$33 M$49 M$66 M2023202420252026

World rank over time

▼ down 862 places since 2022
2022-01-07: #26171#26,17120222022-12-25: #31025#31,02520222023-07-30: #30461#30,46120232024-01-05: #32369#32,36920242026-03-08: #11687#11,68720262026-08-01: #23448#23,44820262026-10-09: #27538#27,53820262026-10-30: #27033#27,0332026

Rank in USA: #4,790 (Jan 2022) · #5,509 (Dec 2022) · #5,293 (Jul 2023) · #4,630 (Jan 2024) · #2,260 (Mar 2026) · #4,099 (Aug 2026) · #4,414 (Oct 2026) · #4,423 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.5×
Free cash flow yield
-92.8%
Net margin
—
Operating margin
—
Return on equity
-339.5%
Liabilities / assets
67.6%
Net debt
$-24M
Revenue growth
-6.4%
R&D / revenue
16.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $8M, net income $-5M$8MFY20Fiscal year ending Dec 2021: revenue $11M, net income $-9M$11MFY21Fiscal year ending Dec 2022: revenue $10M, net income $-10M$10MFY22Fiscal year ending Dec 2023: revenue $10M, net income $-11M$10MFY23Fiscal year ending Dec 2024: revenue $9M, net income $-13M$9MFY24Fiscal year ending Dec 2025: revenue —, net income $-10M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-9M$-10M—
Dec 2024$9M-6.4%$-13M$-13M-134.6%
Dec 2023$10M-4.5%$-11M$-11M-111.8%
Dec 2022$10M-6.6%$-10M$-10M-98.6%
Dec 2021$11M+36.2%$-6M$-9M-80.4%
Dec 2020$8M—$-2M$-5M-56.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-4M$0M$-4M$-2.28—
Dec 2024$-8M$0M$-8M$-17.58—
Dec 2023$-6M$0M$-6M$-24.55—
Dec 2022$-6M$0M$-6M$-1.16—
Dec 2021$-11M$0M$-11M$-2.09—
Dec 2020$-0M$0M$-0M$-4.97—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue $3M, net income $-1M$3MSep ’24Three months to Dec 2024 (from the annual report): revenue $1M, net income $-6M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $-2M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $-1M$1MJun ’25Three months to Sep 2025: revenue $0M, net income $-3M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-5M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-2M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-1M$0MJun ’26

Latest quarter to Jun 2026: revenue $0M (-78.9% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of iSpecimen Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-9 M
Net income
$-10 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$10 M
Total liabilities
$6 M
Total equity
$3 M

As of December-2025

Top 9 institutional investors in iSpecimen Inc.#

As of Sep 30, 2026
9 institutions held 81,043 shares (about 3.2% of the shares outstanding) on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 9 largest institutional investors in iSpecimen Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Citadel Advisors LLC37,165New1.48%$0 MNov 16, 2026
2StoneX Group Inc.16,008New0.64%$0 MNov 3, 2026
3UBS Group AG13,755-18,282 (-57.07%)0.55%$0 MNov 10, 2026
4Geode Capital Management, LLC12,367New0.49%$0 MNov 6, 2026
5Tower Research Capital LLC (TRC)1,649+1,430 (+652.97%)0.07%$0 MNov 16, 2026
6BlackRock, Inc.710 (0.00%)0.00%$0 MNov 13, 2026
7Caitong International Asset Management Co., Ltd24+22 (+1100.00%)0.00%$0 MOct 29, 2026
8Barclays PLC2New0.00%$0 MNov 6, 2026
9SBI Securities Co., Ltd.2+1 (+100.00%)0.00%$0 MOct 22, 2026

Mutual funds holding iSpecimen Inc.#

4 funds hold shares worth $0 M (about 0.3% of the company). Since their previous reports 4 added shares and 0 sold, buying $0 M net.
Mutual funds holding iSpecimen Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC6,558$0 M0.26%<0.01%newMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC44$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC29$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.31$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at iSpecimen Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
12
since
iSpecimen Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Benjamin BielakChief Info Officer & SecretaryBuy+18,000$0.720$13 K84,348Form 4
filed Tracy CurleyCEO, CFO and Treasurer, DirectorBuy+4,400$1.250$6 K49,541Form 4
filed Jill MullanDirectorOption exercise+66,637$1.000$67 K246,226Form 4
filed Christopher IanelliDirectorOption exercise+845$1.000$845425,359Form 4
filed John L. Brooks IIIDirectorGrant or award+125——3,250Form 4
filed Christopher IanelliDirectorGrant or award+92——425,451Form 4
filed Andrew L. RossDirectorGrant or award+125——1.33 MForm 4
filed Steven R. GullansDirectorGrant or award+125——3,250Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: iSpecimen Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
305,211
1 days to cover
Buybacks, Q3 2024
$0M
Q3 2024
Shares sold short, last 24 reportsAll stocks →

Stock splits: 20-for-1 split ; 1-for-5.56 reverse split

iSpecimen Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2024Q3 2024$0M
Q2 2024Q2 2024$0M
Q1 2024Q1 2024$0.1M

Trading halts

  • 2026-04-27 23:50 UTC, code T3, resumed 13:00 UTC
  • 2025-09-09 19:55 UTC, code LUDP, resumed 20:00 UTC
  • 2025-09-09 19:43 UTC, code LUDP, resumed 19:48 UTC
  • 2025-09-09 19:29 UTC, code LUDP, resumed 19:39 UTC
  • 2025-09-09 19:22 UTC, code LUDP, resumed 19:27 UTC

Fails to deliver

  • : 19,085 shares at $0.79
  • : 2,081 shares at $0.84
  • : 3,605 shares at $0.91
  • : 3,958 shares at $1.09
  • : 10,604 shares at $1.26

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

iSpecimen Inc. scorecard#

Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.5×Price to book 1.5× against Diagnostics and Research's median of 3.7×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-92.8%Free cash flow is -92.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.28 vs -17.58Diluted EPS -2.28 in fiscal 2025 against -17.58 the year before (report's currency).
    • ✗Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against -$5 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-327.8%-327.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.12 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

iSpecimen Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

iSpecimen Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue1,9299,2919,92810,40211,1358,184
Cost of revenue1,7135,1114,771r4,7575,2493,585
Research and development—1,4931,6191,474879r319
Selling and marketing2,2964,9453,9563,4452,4231,784
General and administrative3,4726,0675,9356,9335,6132,399
Total costs and expenses10,90722,01921,09820,58817,06110,590
Operating income−8,978−12,728−11,169−10,186−5,925−2,406
Interest and finance income3.744——110.4
Interest expense and finance costs1.9174162392,1032,097
Other non-operating income (expense)−1,51023070−60−3,037−2,246
Income tax———000
Net income attributable to shareholders−10,488−12,498−11,099−10,246−8,962−4,652
Earnings per share, basic-2.28-17.58-24.55r-1.16-2.09-4.97
Earnings per share, diluted-2.28-17.58-24.55r-1.16-2.09-4.97
Shares, weighted average (basic)4.60.70.5r8.84.30.9
Shares, weighted average (diluted)4.60.70.5r8.84.30.9
Balance sheet
Cash and cash equivalents6,8811,8782,34415,30927,739696
Short-term investments——2,6620——
Receivables481,4457281,5983,0021,526
Inventory—45————
Other current assets25220r292300327418
Current assets6,9553,5888,23919,67632,9483,472
Property, plant and equipment26941282263376
Right-of-use (leased) assets269328194185——
Total assets9,5319,35015,81924,61835,7206,210
Accounts payable5,3634,1983,9252,4598331,792
Current liabilities6,2315,7706,0494,2812,50522,136
Lease liabilities (non-current)2122692927——
Total liabilities6,4436,0396,0784,3085,92822,315
Retained earnings−82,350−71,863−59,365−48,265−38,019−29,058
Shareholders' equity3,0883,3119,74120,30929,792−27,278
Total liabilities and equity9,5319,35015,81924,61835,7206,210
Shares outstanding0.2r1.70.5r8.98.70.9
Cash-flow statement
Depreciation and amortization1,7312,2942,115———
Share-based compensation2125046067962293
Cash from operating activities−4,241−8,264−5,808−5,818−10,668−288
Capital expenditure−0.5−32−19−216−2.6−0.4
Intangible assets bought——−958———
Cash from investing activities−1,0001,980−7,228−3,191−1,038−1,103
Debt issued————3,500—
Shares issued4,000398——2,498r—
Cash from financing activities10,2435,81971−3,42138,7492,033
Report10-K10-K10-K10-K10-K/A10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What iSpecimen Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Specimens - contracts with customers(total)$2 M90%
  • Shipping and other$0 M10%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at iSpecimen Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 4 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 9 · Agreement ended 1 · Unregistered share sale 4 · Bylaws or fiscal year changed 4 · Shareholder vote 3

iSpecimen Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Change in controlAcquisition or sale completedMaterial agreementUnregistered share sale8-K
Shareholder vote8-K
Shareholder vote8-K
Delisting notice8-K
Material agreement8-K
Directors and officers8-K
Material agreement8-K
Material agreementAgreement ended8-K
Material agreement8-K
Delisting notice8-K
Shareholder vote8-K
Delisting noticeMaterial agreementUnregistered share sale8-K
Bylaws or fiscal year changed8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K/A
Material agreement8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Delisting notice8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of iSpecimen Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2026$3 MPrivate placement after listing$2 to $10 million2equity, optionsSEC
Dec 2025$6 MPrivate placement after listing$2 to $10 million3equitySEC
Aug 2025$2 MPrivate placement after listingUnder $2 million4equity, optionsSEC
Dec 2021$21 MNo. 3$10 to $50 million4equity, optionsSEC
Aug 2014$9 MNo. 2$2 to $10 million13equitySEC
Aug 2012$2 MNo. 1$2 to $10 million10equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at iSpecimen Inc.#

1 labor condition applications certified in fiscal 2023 for 1 positions, at a median wage of $135 K a year.

Certified, FY2023
1
#2,019 among companies on value.today
Worker positions
1
Median wage offered
$135 K
a year, full-time
Applications filed
1
iSpecimen Inc.: most frequent H-1B job titles in fiscal 2023
Job titlePositionsMedian wage offered
Senior Software EngineerSoftware Developers1$135 K

Where: Lexington, MA 1

iSpecimen Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202311$135 K1
FY202222$120 K2
FY202111$120 K1
FY202022$101 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as iSpecimen Inc.

How iSpecimen Inc. compares in Diagnostics and Research

  • Market cap$5 M · higher than 5% of 110
  • Revenue growth-6.5% · higher than 20% of 89
  • Price / book1.5× · lower than 75% of 84
  • FCF yield-92.8% · higher than 6% of 66

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
iSpecimen Inc.🇺🇸$5 M——-6.5%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 19, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at iSpecimen Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show iSpecimen Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about iSpecimen Inc.? Suggest a correction